Chemotherapy docetaxel

The taxanes (e.g., paclitaxel and docetaxel) are a newer class of agents that rival the anthracyclines in their activity in metastatic breast cancer, becoming (arguably) the most active class of chemotherapy for this disease. 

Chemotherapy, with docetaxel and prednisone or docetaxel and estramustine, improves survival in patients with hormone-refractory prostate cancer. Patients with hormone-refractory prostate cancer should be considered for entry into clinical trials investigating new therapies for prostate cancer. 

Four to six cycles of doublet chemotherapy with cisplatin or carboplatin plus docetaxel, gemcitabine, paclitaxel, or vinorelbine are recommended as first-line chemotherapy for patients with unresectable stage III or IV NSCLC. No combination was found to be superior tolerance of expected toxicities may contribute to the decision. 

Hanna, N. et al.. Randomized phase IE trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, /. Clin. Oncol, 22,... 

Engels FK, Sparreboom A, Mathot RA, Verweij J. (2005) Potential for improvement of docetaxel-based chemotherapy A pharmacological review. Br J Cancer 93 173-177. 

Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9. Use aprepitant with caution in patients receiving concomitant medicinal products, including chemotherapy agents that are primarily metabolized through CYP3A4 (docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, and vincristine). 

Within the multiple subsites of this tumor grouping, most work has been done in esophageal cancer. The large majority of these patients have been treated with paclitaxel in combination with radiation (Table 3). The experience with docetaxel is essentially limited to patients treated on phase I trials for thoracic malignancies that used radiation in combination with docetaxel (68,111). The situation is much the same for both pancreatic and gastric cancers as well. The rationale for looking at combination therapy that incorporates paclitaxel is much the same as in other disease sites, i.e., its activity in systemic disease (112), its potent preclinical radiosensitizing properties (38), and evidence from randomized trials that there is a benefit to combined modality therapy that includes at least radiation and chemotherapy (113-116). 

The initial experience with the taxanes and especially with paclitaxel in the realm of combined modality therapy has had a substantial impact on the treatment of cancers both in the United States and worldwide. Paclitaxel delivered in concert with radiation provides a classical model of the development of clinically applicable treatment strategies from laboratory-based studies. The initial in vitro works of Tishler (39) and Choy (40) have translated in a very tangible way into approaches that are clinically applicable and in the next generation of randomized clinical trials their efficacy will be compared to more traditional chemotherapies in the combined modality setting. While the experience to date with both paclitaxel and docetaxel has been largely positive, the mortality rates in many of the solid tumor types remind us that much more needs to be done. 

Nyman J, Mercke C. Accelerated radiotherapy with docetaxel and cisplatin as induction and concomitant chemotherapy for stage III non-small cell lung cancer. Lung Cancer 2000 29(Suppl 1) 98. 

Varveris H, Delakas D, Anezinis P, et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 1997 17(6D) 4771 1780. 

Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin Seymour MM. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys 2000 48(2) 393-397. 

Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorou-racil, and leuco vorin for squamous cell carcinoma of the head and neck a phase I/II trial. J Clin Oncol 1998 16(4) 1331—1339. 

Posner MR, Glisson B, FrenetteG, etal. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001 19 1096-1104. 

BRCAi A Potential Predictive Marker for CiSPLATIN AND DOCETAXEL BRCAi IN THE Transcriptional Regulation OF Spindle Checkpoint Genes Clinical Trials of Customized Chemotherapy References... 

Fig. 5. Diagram of a potential customized chemotherapy trial based on the expression of NER-related genes. Patients with low levels of BRCAl expression (Ql) are assigned to receive gem-citabine/cisplatin patients with intermediate levels of BRCAl expression (Q2 3) will receive docetaxel/cisplatin patients with high levels of BRCAl expression will receive docetaxel alone.

Taxotere (docetaxel) and Taxol (paclitaxel), both for chemotherapy... 

---